Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #237046 on Biotech Values
DewDiligence
08/20/21 12:06 PM
#239235 RE: DewDiligence #237046
Bristol Myers Squibb today announced that Opdivo (nivolumab) 240 mg every two weeks or 480 mg every four weeks…was approved by the U.S. Food and Drug Administration (FDA) for the adjuvant treatment of patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection, regardless of prior neoadjuvant chemotherapy, nodal involvement or PD-L1 status.